These innovative molecules represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://harleyissx586153.blog-mall.com/39814739/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide